<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(12)</volume><submitter>Saunders N</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide.&lt;h4>Objectives&lt;/h4>The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and impl</pubmed_abstract><journal>PloS one</journal><pagination>e0332430</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12677780</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study.</pubmed_title><pmcid>PMC12677780</pmcid><pubmed_authors>Abrahao A</pubmed_authors><pubmed_authors>Medina YI</pubmed_authors><pubmed_authors>Luth W</pubmed_authors><pubmed_authors>Tremblay-Desbiens C</pubmed_authors><pubmed_authors>Magnussen C</pubmed_authors><pubmed_authors>Das S</pubmed_authors><pubmed_authors>Matte G</pubmed_authors><pubmed_authors>Saunders N</pubmed_authors><pubmed_authors>Abou-Haidar R</pubmed_authors><pubmed_authors>Genuis SK</pubmed_authors><pubmed_authors>Kriz J</pubmed_authors><pubmed_authors>Kang H</pubmed_authors><pubmed_authors>Taylor D</pubmed_authors><pubmed_authors>Yunusova Y</pubmed_authors><pubmed_authors>Bubela T</pubmed_authors><pubmed_authors>Genge A</pubmed_authors><pubmed_authors>Zinman L</pubmed_authors><pubmed_authors>Bowser R</pubmed_authors><pubmed_authors>Johnston WS</pubmed_authors><pubmed_authors>Jones KE</pubmed_authors><pubmed_authors>Karamchandani J</pubmed_authors><pubmed_authors>Velde CV</pubmed_authors><pubmed_authors>Blais M</pubmed_authors><pubmed_authors>Ferry N</pubmed_authors><pubmed_authors>Evans A</pubmed_authors><pubmed_authors>Rogaeva E</pubmed_authors><pubmed_authors>Dhanoa A</pubmed_authors><pubmed_authors>Bouvier L</pubmed_authors><pubmed_authors>Graham SJ</pubmed_authors><pubmed_authors>Pfeffer G</pubmed_authors><pubmed_authors>Boivin MN</pubmed_authors><pubmed_authors>Anand T</pubmed_authors><pubmed_authors>Seres P</pubmed_authors><pubmed_authors>Tam F</pubmed_authors><pubmed_authors>Dupre N</pubmed_authors><pubmed_authors>Frater Y</pubmed_authors><pubmed_authors>Kalra S</pubmed_authors><pubmed_authors>Chiappini J</pubmed_authors><pubmed_authors>Robertson J</pubmed_authors><pubmed_authors>Bhinder H</pubmed_authors><pubmed_authors>Greiner R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study.</name><description>&lt;h4>Background&lt;/h4>The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide.&lt;h4>Objectives&lt;/h4>The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and impl</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-05T23:19:47.465Z</modification><creation>2026-05-23T03:13:55.254Z</creation></dates><accession>S-EPMC12677780</accession><cross_references><pubmed>41343582</pubmed><doi>10.1371/journal.pone.0332430</doi></cross_references></HashMap>